drugset / Trial / NCT04296864
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Phase 2
Unknown
42 enrolled
Andover Eye Associates
Regeneron Pharmaceuticals · collabStatistics & Data Corporation · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic keratoconjunctivitis (AKC).
Timeline
- Start
- 2020-02-10
- Primary completion
- 2025-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | 300 mg | — |